Literature DB >> 9811874

Carcinogen-induced loss of heterozygosity at the Aprt locus in somatic cells of the mouse.

S W Wijnhoven1, P P Van Sloun, H J Kool, G Weeda, R Slater, P H Lohman, A A van Zeeland, H Vrieling.   

Abstract

Genetic events leading to the loss of heterozygosity (LOH) have been shown to play a crucial role in the development of cancer. However, LOH events do not occur only in genetically unstable cancer cells but also have been detected in normal somatic cells of mouse and man. Mice, in which one of the alleles for adenine phosphoribosyltransferase (Aprt) has been disrupted by gene targeting, were used to investigate the potency of carcinogens to induce LOH in vivo. After 7,12-dimethyl-1,2-benz[a]anthracene (DMBA) exposure, a 3-fold stronger mutagenic response was detected at the autosomal Aprt gene than at the X chromosomal hypoxantine-guanine phosphoribosyltransferase (Hprt) gene in splenic T-lymphocytes. Allele-specific PCR analysis showed that the normal, nontargeted Aprt allele was lost in 70% of the DMBA-induced Aprt mutants. Fluorescence in situ hybridization analysis demonstrated that the targeted allele had become duplicated in almost all DMBA-induced mutants that displayed LOH at Aprt. These results indicate that the main mechanisms by which DMBA caused LOH were mitotic recombination or chromosome loss and duplication but not deletion. However, after treatment with the alkylating agent N-ethyl-N-nitrosourea, Aprt had a similar mutagenic response to Hprt while the majority (90%) of N-ethyl-N-nitrosourea-induced Aprt mutants had retained both alleles. Unexpectedly, irradiation with x-rays, which induce primarily large deletions, resulted in a significant increase of the mutant frequency at Hprt but not at Aprt. This in vivo study clearly indicates that, in normal somatic cells, carcinogen exposure can result in the induction of LOH events that are compatible with cell survival and may represent an initiating event in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811874      PMCID: PMC24893          DOI: 10.1073/pnas.95.23.13759

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  DNA sequence analysis of hprt mutations in lymphocytes from Sprague-Dawley rats treated with 7,12-dimethylbenz[a]anthracene.

Authors:  R H Heflich; R A Mittelstaedt; M G Manjanatha; L E Lyn-Cook; A Aidoo
Journal:  Environ Mol Mutagen       Date:  1996       Impact factor: 3.216

Review 2.  Lessons from hereditary colorectal cancer.

Authors:  K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

Review 3.  Clinical implications of the p53 tumor-suppressor gene.

Authors:  C C Harris; M Hollstein
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

4.  Isolation and molecular characterization of spontaneous mutants of lymphoblastoid cells with extended loss of heterozygosity.

Authors:  A G de Nooij-van Dalen; V H van Buuren-van Seggelen; A Mulder; K Gelsthorpe; J Cole; P H Lohman; M Giphart-Gassler
Journal:  Mutat Res       Date:  1997-03-04       Impact factor: 2.433

5.  High frequency in vivo loss of heterozygosity is primarily a consequence of mitotic recombination.

Authors:  P K Gupta; A Sahota; S A Boyadjiev; S Bye; C Shao; J P O'Neill; T C Hunter; R J Albertini; P J Stambrook; J A Tischfield
Journal:  Cancer Res       Date:  1997-03-15       Impact factor: 12.701

6.  APRT: a versatile in vivo resident reporter of local mutation and loss of heterozygosity.

Authors:  P J Stambrook; C Shao; M Stockelman; G Boivin; S J Engle; J A Tischfield
Journal:  Environ Mol Mutagen       Date:  1996       Impact factor: 3.216

7.  Allelotypic and cytogenetic characterization of chemically induced mouse mammary tumors: high frequency of chromosome 4 loss of heterozygosity at advanced stages of progression.

Authors:  C M Aldaz; Q Y Liao; A Paladugu; S Rehm; H Wang
Journal:  Mol Carcinog       Date:  1996-11       Impact factor: 4.784

8.  Evidence for high-frequency allele loss at the aprt locus in TK6 human lymphoblasts.

Authors:  L E Smith; A J Grosovsky
Journal:  Mutat Res       Date:  1993-10       Impact factor: 2.433

9.  Frequency and spectrum of ethylnitrosourea-induced mutation at the hprt and lacI loci in splenic lymphocytes of exposed lacI transgenic mice.

Authors:  V E Walker; N J Gorelick; J L Andrews; T R Craft; J G deBoer; B W Glickman; T R Skopek
Journal:  Cancer Res       Date:  1996-10-15       Impact factor: 12.701

10.  Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53.

Authors:  M F Denissenko; A Pao; M Tang; G P Pfeifer
Journal:  Science       Date:  1996-10-18       Impact factor: 47.728

View more
  5 in total

1.  X-rays induce distinct patterns of somatic mutation in fetal versus adult hematopoietic cells.

Authors:  Li Liang; Li Deng; Marc S Mendonca; Yanping Chen; Betty Zheng; Peter J Stambrook; Changshun Shao; Jay A Tischfield
Journal:  DNA Repair (Amst)       Date:  2007-06-05

2.  Mutator phenotypes conferred by MLH1 overexpression and by heterozygosity for mlh1 mutations.

Authors:  P V Shcherbakova; T A Kunkel
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

3.  Carcinogens induce genome-wide loss of heterozygosity in normal stem cells without persistent chromosomal instability.

Authors:  Sarah L Donahue; Qing Lin; Shang Cao; H Earl Ruley
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-25       Impact factor: 11.205

4.  In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I.

Authors:  K Manning; M Al-Dhalimy; M Finegold; M Grompe
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

5.  Spontaneous mitotic homologous recombination at an enhanced yellow fluorescent protein (EYFP) cDNA direct repeat in transgenic mice.

Authors:  Carrie A Hendricks; Karen H Almeida; Molly S Stitt; Vidya S Jonnalagadda; Rebecca E Rugo; G Foster Kerrison; Bevin P Engelward
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-15       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.